Abstract
The histological gastric stage (OLGA) plays an important role in evaluating gastric atrophy, a symptom which suggests a risk of gastric cancer (GC). However, gastroscopy is an invasive examination, which has limited application in populations undergoing physical examination. Serum pepsinogen (PG) and gastin-17 (G-17) levels are noninvasive indexes which are recommended when screening for GC. We aim to explore the correlation between PG/G-17 and OLGA stage, in order to provide reliable indexes for GC screening. The study included 453 asymptomatic individuals from East China undergoing physical examination, who then underwent endoscopy including collection of biopsy samples. Assays for serum PG, G-17, and Helicobacter pylori (Hp) were performed. Atrophy of gastric mucosa was graded according to OLGA for each individual. 453 participants, average age 52.46 ± 10.30 years, 253 male and 200 female, were included. In the asymptomatic physical examination population, serum PGI, PGII, and PGR levels decreased with increasing OLGA scores. PGI and PGR were inversely correlated with increasing OLGA stage in both Hp-positive and Hp-negative groups. The levels of serum PGI, PGII, and G-17 in the Hp-positive group were higher than those in the Hp-negative group; conversely, the PGR levels were lower. Furthermore, OLGA scores increased with age in the Hp-positive group. In conclusion, there is a significant correlation between OLGA stage and serum PG in populations from East China undergoing physical examination. Serum PG and G-17 combined with Hp test plays an important role in evaluating gastric atrophy.
Highlights
IntroductionGastric cancer (GC) is the fifth most common cancer in the world
Gastric cancer (GC) is the fifth most common cancer in the world.Approximately 1 million GC cases are newly diagnosed and almost 700,000 people die from this disease annually, which accounts for 10% of the world’s cancer-related deaths [1]
There is a significant difference in the survival rate between those diagnosed with early GC and advanced GC [11]; the reason for this is a lack of effective treatments for advanced GC
Summary
Gastric cancer (GC) is the fifth most common cancer in the world. 1 million GC cases are newly diagnosed and almost 700,000 people die from this disease annually, which accounts for 10% of the world’s cancer-related deaths [1]. The areas with the highest incidence of GC are Eastern Europe, East Asia, and parts of central and Southern America, while with the lowest in Southern Asia, North and East Africa, Australia and North America [2]. GC is the second most common cancer in China, after lung cancer [3]. Gastric cancer has a better prognosis, with a 5-year survival rate of more than 90%, while the 5-year survival rate of advanced gastric cancer is less than 40%. To reduce the incidence of GC, early diagnosis and active intervention are essential
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call